Ginkgo Bioworks
DNA
260 hedge funds and large institutions have $1.93B invested in Ginkgo Bioworks in 2022 Q2 according to their latest regulatory filings, with 101 funds opening new positions, 78 increasing their positions, 40 reducing their positions, and 28 closing their positions.
261% more first-time investments, than exits
New positions opened: 101 | Existing positions closed: 28
95% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 40
37% more funds holding
Funds holding: 190 → 260 (+70)
33% more call options, than puts
Call options by funds: $14.3M | Put options by funds: $10.8M
0.53% more ownership
Funds ownership: 1.27% → 1.8% (+0.53%)
28% less capital invested
Capital invested by funds: $2.68B → $1.93B (-$746M)
33% less funds holding in top 10
Funds holding in top 10: 12 → 8 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$175M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$115M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$69.6M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$66.6M |
| 5 |
BlackRock
New York
|
+$50M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIG
Senator Investment Group
New York
|
-$106M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$73.1M |
| 3 |
GA
General Atlantic
New York
|
-$65.2M |
| 4 |
HF
HRT Financial
New York
|
-$30.6M |
| 5 |
CC
Casdin Capital
New York
|
-$16.9M |
DNA Hedge Fund Activity: Q2 2022 in Review
260 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks (DNA) for Q2 2022, worth a combined $1.93B — down 28% from $2.68B a quarter earlier.
Buyers outnumbered sellers: 101 funds opened new DNA positions and 28 closed out — a net gain of 73 holders — while 78 added to existing stakes and 40 trimmed.
The largest buyer was Vanguard Group, adding an estimated $175M. The largest seller was Senator Investment Group, cutting an estimated $106M.
- 260 institutional investors held Ginkgo Bioworks (DNA) as of Q2 2022, up from 190 in Q1 2022.
- Funds reported $1.93B of Ginkgo Bioworks stock for Q2 2022, down 28% quarter-over-quarter.
- 101 funds opened new Ginkgo Bioworks positions in Q2 2022 and 28 closed out, a net change of +73 holders.
- The largest Ginkgo Bioworks buyer in Q2 2022 was Vanguard Group, an estimated $175M added.
- The largest Ginkgo Bioworks seller in Q2 2022 was Senator Investment Group, an estimated $106M sold.
Based on aggregated 13F filings for Q2 2022.